<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="14321,29987">Glutamate</z:chebi> acting on <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) receptors induces neuronal injury following <z:hpo ids='HP_0001297'>stroke</z:hpo>, through activation of poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase-1 (PARP-1) and generation of the <z:hpo ids='HP_0011420'>death</z:hpo> molecule poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) (PAR) polymer </plain></SENT>
<SENT sid="1" pm="."><plain>Here we identify Iduna, a previously undescribed <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor-induced survival protein that is neuroprotective against <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor-mediated excitotoxicity both in vitro and in vivo and against <z:hpo ids='HP_0001297'>stroke</z:hpo> through interfering with PAR polymer-induced cell <z:hpo ids='HP_0011420'>death</z:hpo> (parthanatos) </plain></SENT>
<SENT sid="2" pm="."><plain>Iduna's protective effects are independent and downstream of PARP-1 activity </plain></SENT>
<SENT sid="3" pm="."><plain>Iduna is a PAR polymer-binding protein, and mutation at the PAR polymer binding site abolishes the PAR binding activity of Iduna and attenuates its protective actions </plain></SENT>
<SENT sid="4" pm="."><plain>Iduna is protective in vivo against <z:chebi fb="0" ids="31882">NMDA</z:chebi>-induced excitotoxicity and middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>-induced <z:hpo ids='HP_0001297'>stroke</z:hpo> in mice </plain></SENT>
<SENT sid="5" pm="."><plain>To our knowledge, these results define Iduna as the first known endogenous inhibitor of parthanatos </plain></SENT>
<SENT sid="6" pm="."><plain>Interfering with PAR polymer signaling could be a new therapeutic strategy for the treatment of <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurologic disorders</z:e> </plain></SENT>
</text></document>